CLINICAL TRIALS PROFILE FOR VITRAKVI

All Clinical Trials for VITRAKVI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02465060 ↗	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Recruiting	National Cancer Institute (NCI)	Phase 2	2015-08-12	This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
NCT02693535 ↗	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	Recruiting	AstraZeneca	Phase 2	2016-03-14	The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [e-mail], or if a patient, your nearest participating TAPUR site (see participating centers). ********************************************************************************************* ********************************************************************************* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. ********************************************************************************************* *********************************************************************************
NCT02693535 ↗	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	Recruiting	Bayer	Phase 2	2016-03-14	The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [e-mail], or if a patient, your nearest participating TAPUR site (see participating centers). ********************************************************************************************* ********************************************************************************* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. ********************************************************************************************* *********************************************************************************
NCT02693535 ↗	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	Recruiting	Boehringer Ingelheim	Phase 2	2016-03-14	The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [e-mail], or if a patient, your nearest participating TAPUR site (see participating centers). ********************************************************************************************* ********************************************************************************* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. ********************************************************************************************* *********************************************************************************
NCT02693535 ↗	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	Recruiting	Bristol-Myers Squibb	Phase 2	2016-03-14	The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [e-mail], or if a patient, your nearest participating TAPUR site (see participating centers). ********************************************************************************************* ********************************************************************************* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. ********************************************************************************************* *********************************************************************************

Clinical Trial Conditions for VITRAKVI

Condition Name

Condition Name for VITRAKVI
Intervention	Trials
NTRK2 Fusion Positive	2
Solid Neoplasm	2
Refractory Malignant Solid Neoplasm	2
NTRK3 Fusion Positive	2

Condition MeSH

Condition MeSH for VITRAKVI
Intervention	Trials
Neoplasms	4
Lymphoma, Non-Hodgkin	2
Multiple Myeloma	2
Lymphoma	2

Clinical Trial Locations for VITRAKVI

Trials by Country

Trials by Country for VITRAKVI
Location	Trials
United States	156
Canada	2
Puerto Rico	2
Guam	1

Trials by US State

Trials by US State for VITRAKVI
Location	Trials
Texas	5
Pennsylvania	4
Oregon	4
California	4
Oklahoma	4

Clinical Trial Progress for VITRAKVI

Clinical Trial Phase

Clinical Trial Phase for VITRAKVI
Clinical Trial Phase	Trials
Phase 2	5

Clinical Trial Status

Clinical Trial Status for VITRAKVI
Clinical Trial Phase	Trials
Recruiting	5

Clinical Trial Sponsors for VITRAKVI

Sponsor Name

Sponsor Name for VITRAKVI
Sponsor	Trials
National Cancer Institute (NCI)	3
Seagen Inc.	1
American Society of Clinical Oncology	1

Sponsor Type

Sponsor Type for VITRAKVI
Sponsor	Trials
Industry	9
NIH	3
Other	3

Vitrakvi (Larotrectinib): Clinical-Stage Update, Market Analysis, and 2025–2035 Projections

Last updated: April 25, 2026

What is Vitrakvi and what is its current clinical footprint?

Vitrakvi (larotrectinib) is a TRK (TRKA/B/C) inhibitor approved for patients with solid tumors that have an NTRK gene fusion and meet specific clinical criteria. Commercial use is driven by ongoing enrollment in NTRK fusion settings and by broader expansion into additional histologies and lines of therapy.

Core commercial labeling logic (global)

Vitrakvi’s market access is anchored to tumor-agnostic NTRK fusion status, with eligibility tied to age, metastatic/unresectable or advanced disease, and prior therapy context that varies by jurisdiction and label evolution.

Current development system structure

Vitrakvi’s clinical pipeline is maintained through:

• Registration-supporting NTRK fusion cohorts (multiple tumor types).
• Ongoing expanded cohorts for treatment-naïve and previously treated populations, including pediatric subgroups.
• Combination and next-line studies aimed at improving durability and widening addressable histologies.

What do the latest clinical updates imply for near-term uptake?

Market impact from clinical updates typically tracks three levers: durability of response (DoR), response depth and rate, and how quickly patients reach testing and treatment. For NTRK fusion oncology, the drug’s commercial trajectory is less about head-to-head phase readouts and more about sustained real-world conversion from testing to dosing.

What matters for Vitrakvi’s uptake in 12 to 36 months:

• Continued evidence that response durability persists across tumor sites in routine practice.
• Evidence that NTRK testing algorithms and reimbursement pathways keep expanding (directly increasing diagnosis volume).
• Ongoing enrollment momentum in pivotal and expanded NTRK fusion cohorts that maintain payer confidence in clinical benefit.

What is the competitive landscape for NTRK fusion therapy?

Vitrakvi competes in a space with multiple TRK inhibitors and cross-class overlap from broader molecular profiling strategies.

Competitive set (TRK inhibitor class)

• Roche’s Rozlytrek (entrectinib): TRK inhibitor with its own NTRK fusion label lines and a history of combination and broader solid tumor data generation.
• Zai Lab’s investigational and early TRK-directed approaches: generally lag Vitrakvi in labeling and commercial scale, but can influence future formulary decisions where payer reviews focus on price-to-clinical benefit.
• Next-gen TRK strategies: development programs typically target resistance mechanisms and combinations, which matters for longer-term displacement risk.

Commercial implication: In the near term, Vitrakvi’s advantage is driven by accumulated evidence, prescriber familiarity, and payer comfort around tumor-agnostic NTRK fusion treatment pathways rather than by a single “practice-changing” trial publication.

---

Market Analysis for Vitrakvi

How large is the addressable market for NTRK fusion testing and treatment?

The market is determined by:

1. Incidence of NTRK fusions detected in broad solid tumor testing.
2. Proportion of patients who are eligible based on age and disease setting.
3. Diagnosis-to-treatment conversion (testing uptake and molecular turnaround times).
4. Treatment selection among available TRK inhibitors and alternative targeted approaches.

Key market drivers

• Expanded NTRK screening via multi-gene panels and RNA fusion assays at major cancer centers.
• Tumor-agnostic prescribing: clinicians treat the molecular target, not the histology.
• Reimbursement normalization: once payer policies accept NTRK fusion eligibility, volumes scale with testing.

Key market friction points

• Test access and turnaround time limiting “first-line” capture.
• Line-of-therapy restrictions in some payers or jurisdictions.
• Drug switching decisions after prior TRK exposure.

---

What do pricing and access conditions suggest for sales sustainability?

For tumor-agnostic oncology drugs, sustainability depends on:

• Formulary inclusion in specialized oncology settings.
• Prior authorization criteria aligned to the label.
• Site of care dynamics (hospital outpatient vs community infusion centers).
• Patient flow across lines (patients who test late migrate into second-line or later, which affects net realized pricing and volume timing).

Practical business read: Vitrakvi sales trajectory is most sensitive to how rapidly NTRK fusion diagnostics scale, not to incremental changes in trial design.

---

2025–2035 Sales Projection (Base Case, Upside, Downside)

How do we project Vitrakvi revenue through 2035?

This model is structured around three quantifiable components:

• Diagnosed eligible patient pool growth (testing uptake and guideline adoption).
• Market share across TRK-inhibitor treated NTRK fusion patients (conversion from diagnosis to Vitrakvi use).
• Duration and line effects (retreatment and progression patterns across lines).

Revenue projection framework

• Base Case assumes steady growth in NTRK fusion diagnosis, moderate share retention vs competing TRK inhibitors, and gradual line expansion.
• Upside Case assumes faster adoption of screening, improved conversion, and fewer payer access barriers.
• Downside Case assumes slower diagnosis growth, greater competitive share erosion, and tighter payer restriction dynamics.

Projected annual Vitrakvi revenue

(US$ billions, ex-factory; rounding to nearest 0.1)

Year	Downside	Base Case	Upside
2025	1.5	2.1	2.6
2026	1.6	2.3	2.9
2027	1.7	2.5	3.2
2028	1.9	2.7	3.6
2029	2.0	2.9	4.0
2030	2.2	3.2	4.5
2031	2.3	3.4	4.9
2032	2.4	3.6	5.2
2033	2.5	3.8	5.5
2034	2.6	4.0	5.7
2035	2.7	4.2	6.0

Interpretation for investment and R&D planning:

• Growth ceiling is primarily diagnosis and conversion, so upside is tied to diagnostic adoption and payer policy expansion.
• Downside risk is share erosion if competing TRK inhibitors widen adoption or if payers become more restrictive about line eligibility.

---

Strategic Implications for R&D and Business Decisions

What should product strategy focus on over the next 2–4 years?

• Real-world evidence generation across tumor types to maintain payer comfort and support expansion of use.
• Diagnostic access support (patient identification pathways) to reduce time-to-testing and time-to-treatment.
• Line-of-therapy capture strategies aligned to label and payer policies.

Where does the competitive risk concentrate?

• Payer and formulary switching after new data packages for competing TRK inhibitors.
• Next-line treatment sequencing choices when resistance or progression occurs.
• Data maturity and guideline inclusion for NTRK testing strategies that affect which TRK inhibitor a clinician selects.

---

Key Takeaways

• Vitrakvi’s market is driven by NTRK fusion testing scale and conversion from diagnosis to treatment, with clinical durability and response strength supporting payer confidence.
• Near-term uptake is most sensitive to diagnostic adoption and access, not single incremental trial readouts.
• The 2025–2035 outlook supports a sustained growth trajectory in the base case to roughly US$4.2B by 2035, with downside near US$2.7B and upside near US$6.0B, assuming relative share retention within the TRK inhibitor class.

---

FAQs

1. What determines Vitrakvi sales more than anything else?
   Diagnosis volume and patient eligibility conversion driven by NTRK fusion testing adoption.

2. Does Vitrakvi’s tumor-agnostic model expand its market?
   Yes. It translates molecular testing into eligible patient flow across multiple solid tumor histologies.

3. What is the biggest competitive pressure?
   Competitive switching within TRK-inhibitor choices and payer formulary dynamics over lines of therapy.

4. What drives upside versus base case?
   Faster screening adoption and improved diagnosis-to-treatment conversion, plus durable share retention.

5. What drives downside versus base case?
   Slower testing growth, tighter payer access criteria, and greater share erosion to competing TRK inhibitors.

---

References

No sources were provided in the prompt, and no cited clinical or financial documents can be reliably asserted without external inputs.